Valeant Pharmaceuticals International Inc $117.30

up +0.44


29/8/2014 04:02 PM  |  NYSE : VRX  
Industries : Drugs / Drug Delivery & Accessories
Get Trend Analysis Icon Get VRX Trend Analysis - it has underperformed the S&P 500 by 4%

Partner Headlines

  1. Hedge Fund Manager Bill Ackman with a Very Profitable Year

    GuruFocus
  2. Gilead, Jazz Among 4 Top Big Cap Medicals To Watch

    IBD
  3. IBD's Special 8-Week Hold Rule Has Faced Tough 2014

    IBD
  4. SALIX PHARMACEUTICALS

    IBD
  5. Benzinga's M&A Chatter for Tuesday August 19, 2014

    Benzinga
  6. Salix Soars On Allergan Buzz

    IBD
  7. Indexes Rally On Strong Housing Data, Retail Reports

    IBD
  8. Allergan Reportedly Eyes Salix To Avoid Valeant Deal

    IBD
  9. Allergan Takes In 13 New Hedge Fund Investments In Q2

    Benzinga
  10. Markets Gather Some Momentum As Volume Remains Light, Geopolitical Tension ...

    Benzinga
  11. Benzinga's M&A Chatter for Monday August 11, 2014

    Benzinga
  12. Valeant Pharmaceuticals'

    IBD
  13. Valeant Pharmaceuticals Part X: a follow up on the sale of facial injectables

    GuruFocus
  14. Allergan Rebounds After Analyst Upgrades On Valuation

    IBD
  15. Prescription Drugmakers Slide Down Industry Rankings

    IBD
  16. Salix, Actavis Lead IBD 50 Drug Earnings This Week

    IBD
  17. Thursday's Selling Momentum Continues In To Friday

    Benzinga
  18. Thursday's Selling Momentum Continues Into Friday

    Benzinga
  19. Valeant, Ackman's Pershing Square Issue Response to 'Frivolous Allergan ...

    Benzinga
  20. Valeant Guides Outlook Low

    IBD
  21. Dow Suffers 300 Point Drop; S&P 500 And Nasdaq Also Tumble

    Benzinga
  22. Valeant Q2 Meets Views; Guidance Down On Asset Sale

    IBD
  23. UPDATE: Valeant Pharmaceuticals Posts Higher Q2 Profit

    Benzinga
  24. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD
  25. Diamond Hill Capital Comments on Valeant Pharmaceuticals International ...

    GuruFocus
  26. BTIG: Valeant Must Sweeten Allergan Bid To More Than $200/Share

    Benzinga
  27. Allergan EPS Gains Accelerate

    IBD
  28. Allergan Earnings Growth, Job Cuts Counter Valeant

    IBD
  29. UPDATE: Valeant Complains to SEC Regarding Allergan Claims

    Benzinga
  30. Valeant Submits HSR Filing Related to Proposed Allergan Deal

    Benzinga
  31. Benzinga's M&A Chatter for Wednesday July 9, 2014

    Benzinga
  32. Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking ...

    Benzinga
  33. Chipotle, Keurig Near Buy Points; Energy Dominates

    IBD
  34. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  35. Benzinga's M&A Chatter for Wednesday June 25, 2014

    Benzinga
  36. Paulson builds Allergan stake

    IBD
  37. Rumor: Big Stake In Allergan Acquired By Valeant Supporter Paulson

    Benzinga
  38. Markets Close Higher Despite A Contraction In GDP

    Benzinga
  39. Benzinga's M&A Chatter for Tuesday June 24, 2014

    Benzinga
  40. Indexes Mixed As Stocks Pare Earlier Gains

    IBD
  41. Walgreen Falls On Weak Earnings, Alliance Boots Reset

    IBD
  42. 'Merger Monday' Deals, Offers And Rejections

    Benzinga
  43. Allergan Rebuffs Valeant's Tender Offer

    FoxBusiness
  44. Akorn

    IBD
  45. Akorn Shares Gaining On $41 Million Sale Of Branded Drugs Unit To Valeant

    Benzinga
  46. Shire Rejects AbbVie's $46 Bil Tax-Inversion Attempt

    IBD
  47. Valeant launches hostile bid

    IBD
  48. M&A Activity Helps Fuel Healthy Action In Drugmakers

    IBD
  49. Benzinga's M&A Chatter for Wednesday June 18, 2014

    Benzinga
  50. 5-Star Biotech Stock Watch: Synta Pharmaceuticals

    Benzinga
Trading Center